Last updated on February 2018
SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease
Brief description of study
To investigate the efficacy of the administration of JVS-100 delivered via direct intramuscular injections on a 3 month and 6 month composite endpoint of wound progression, healing and limb loss in patients with severe peripheral arterial disease with non-healing chronic wounds who undergo an open bypass grafting or endovascular procedure for treatment of infrapopliteal disease and are dosed within 12 days and 3 months following the procedure.
Clinical Study Identifier: NCT02544204
Start Over
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
